Galectin Therapeutics (GALT) Net Income towards Common Stockholders (2010 - 2026)
Galectin Therapeutics (GALT) recorded quarterly Net Income towards Common Stockholders of -$5.1 million in Q1 2026, up 8.9% quarter-over-quarter from -$5.6 million in Q4 2025, and up 47.25% on a YoY basis from -$3.4 million in Q1 2025.
Galectin Therapeutics (GALT) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$5.1 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 47.25% year-over-year to -$5.1 million; the TTM figure through Mar 2026 stood at -$26.4 million (up 41.65% YoY), while the FY2025 annual figure was -$31.0 million, up 34.38% from the prior year.
- Net Income towards Common Stockholders was -$5.1 million for Q1 2026 at Galectin Therapeutics, up from -$5.6 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.1 million in Q1 2026 to a low of -$14.0 million in Q3 2023.
- Historically, Net Income towards Common Stockholders has averaged -$9.8 million across 5 years, with a median of -$9.9 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders sank 63.63% in 2023, then surged 53.77% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$10.7 million in 2022, then increased by 5.97% to -$10.1 million in 2023, then fell by 19.58% to -$12.0 million in 2024, then soared by 53.77% to -$5.6 million in 2025, then climbed by 8.9% to -$5.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$5.1 million (Q1 2026), -$5.6 million (Q4 2025), and -$8.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - | -5.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.07 Mn |
| Dec 31, 2025 | -5.56 Mn |
| Sep 30, 2025 | -8.22 Mn |
| Jun 30, 2025 | -7.58 Mn |
| Mar 31, 2025 | -9.61 Mn |
| Dec 31, 2024 | -12.03 Mn |
| Sep 30, 2024 | -11.24 Mn |
| Jun 30, 2024 | -12.44 Mn |
| Mar 31, 2024 | -11.50 Mn |
| Dec 31, 2023 | -10.06 Mn |
| Sep 30, 2023 | -14.04 Mn |
| Jun 30, 2023 | -9.18 Mn |
| Mar 31, 2023 | -11.53 Mn |
| Dec 31, 2022 | -10.70 Mn |
| Sep 30, 2022 | -8.58 Mn |
| Jun 30, 2022 | -9.68 Mn |
| Mar 31, 2022 | -9.92 Mn |
| Dec 31, 2021 | -7.29 Mn |
| Sep 30, 2021 | -8.56 Mn |
| Jun 30, 2021 | -8.51 Mn |